Gender, race, and HIV therapy: Insights from the GRACE study

May 30, 2013
©2013 Mary Ann Liebert, Inc., publishers

Enrollment of women in clinical trials of new anti-HIV drugs is extremely low, representing only about 15% of all treatment-experienced patients. For women of color it is even lower. Why women, and especially women of color, are so poorly represented in HIV drug trials is the focus of an important article in AIDS Patient Care and STDs, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

HIV-infected individuals that participated in the GRACE study, conducted from October 2006-December 2008, received based on a darunavir/ritonavir . More than half of the trial participants completed a survey between 2010-2011 to evaluate their experiences, opinions, and outcomes. The survey showed that 76% of the respondents felt that the GRACE trial made them feel differently about their health/HIV care, 82% became more focused on their health, and 87% continued treatment after GRACE.

Access to treatment was reported as the most positive factor in patient enrollment, according to authors Kathleen Squires and colleagues from Jefferson Medical College of Thomas Jefferson University (Philadelphia, PA), University of Cincinnati College of Medicine (OH), The Well Project, Inc. (Nellysford, VA), University of California, Los Angeles, Janssen Research & Development, and Janssen Services (Titusville, NJ).

Factors associated with difficulties in adherence to HIV medications, a critical part of maintaining healthy lives, included being the primary caregiver for children, unemployment, and transportation difficulties. These findings were reported in the article "Insights on GRACE (Gender, Race, and Clinical Experience) from the Patient's Perspective: GRACE Participant Survey."

"Identification of patients at high risk for suboptimal clinical trial outcomes through surveys such as these should help improve HIV medication compliance and retention," says Editor-in-Chief Jeffrey Laurence, MD, Director of the Laboratory for AIDS Virus Research at Weill Medical College of Cornell University, New York, NY.

Explore further: Are there gender differences in anti-HIV drug efficacy?

More information: The article is available free on the AIDS Patient Care and STDs website at

Related Stories

Are there gender differences in anti-HIV drug efficacy?

August 9, 2012

Women comprise nearly half of the HIV-infected population worldwide, but these 15.5 million women tend to be under-represented in clinical trials of anti-HIV drug therapies. The U.S. Food and Drug Administration (FDA) has ...

Can specialized HIV community pharmacies improve treatment?

August 14, 2012

Community pharmacies with specially trained staff to provide HIV services can help HIV-infected individuals be more compliant with their essential antiviral drug regimens and hence improve patient outcomes. Users of HIV-specialized ...

Patient satisfaction leads to better HIV care

January 30, 2013

In a study of patients at two HIV clinics in the Houston area, researchers at Baylor College of Medicine and the Michael E. DeBakey Veterans Affairs Medical Center found that those who were satisfied with the care they received ...

Integrating mental health care into HIV care

May 21, 2013

The integration of mental health interventions into HIV prevention and treatment platforms can reduce the opportunity costs of care and improve treatment outcomes, argues a new Policy Forum article published in this week's ...

Recommended for you

Videos reveal how HIV spreads in real time

October 2, 2015

How retroviruses like HIV spread in their hosts had been unknown—until a Yale team devised a way to watch it actually happen in a living organism. The elaborate and sometimes surprising steps the virus takes to reach and ...

Researchers find proteins that shut down HIV-1

September 30, 2015

A pair of studies by researchers at the University of Massachusetts Medical School, the University of Trento in Italy, and the University of Geneva in Switzerland, point to a promising new anti-retroviral strategy for combating ...

An antibody that can attack HIV in new ways

September 11, 2015

Proteins called broadly neutralizing antibodies (bNAbs) are a promising key to the prevention of infection by HIV, the virus that causes AIDS. bNAbs have been found in blood samples from some HIV patients whose immune systems ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.